Diabetes, Obesity & Metabolism
Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study
By Dvora Rywka Sehtman-Shachar, Alisa Fishkin, Gil Leibowitz, Show 2 more authorsGenya Aharon-Hananel
Cohort study of 4,554 peopleInterventions
2.5 years
- GLP-1 receptor agonists
- Tirzepatide
- GLP-1 and incretin signalling
- Type 2 diabetes
- Chronic kidney disease
- Humans
The paper
Hebrew University of Jerusalem
Diabetes, Obesity & Metabolism, 7 Oct 2026
